Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Aditya R, Bothra"'
Autor:
Saurabh Singh, Deepak Jeswani, Sameer Haveri, Apurva Agarwal, Rajat Choudhuri, Gursaran Kaur Sidhu, Nilesh Agrawal, Gyan Singh, Anil Gulati, Aditya R. Bothra, Parvez David Haque, Prashant Rahate, Ajay K. Gupta, Sanjeev Maheshwari, S. K. Noushad Ali
Publikováno v:
Drugs. 81:1079-1100
Centhaquine (Lyfaquin®) showed significant safety and efficacy in preclinical and clinical phase I and II studies. A prospective, multicentric, randomized phase III study was conducted in patients with hypovolemic shock, systolic blood pressure (SBP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3472d3f481dd2ac5de101eb3e75cfa96
https://doi.org/10.1007/s40265-021-01547-5
https://doi.org/10.1007/s40265-021-01547-5
Autor:
Apurva Agarwal, G. P. Singh, Aditya R. Bothra, Prashant Rahate, S. K. Noushad Ali, Saurabh Singh, Ajay Gupta, Nilesh Agrawal, Gursaran Kaur Sidhu, Anil Gulati, Rajat Choudhuri, Deepak Jeswani, Sameer Haveri, Sanjeev Maheshwari, Parvez David Haque
Publikováno v:
Circulation. 142
Background: Centhaquine (CQ) is a novel, first-in-class resuscitative agent for the treatment of hypovolemic shock. Methods: Efficacy of CQ for the treatment of hypovolemic shock as an adjuvant to standard of care (SOC) was evaluated in a prospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b380eba9f65c358bc256279415ec7b88
https://doi.org/10.1161/circ.142.suppl_4.118
https://doi.org/10.1161/circ.142.suppl_4.118
Autor:
Anil, Gulati, Rajat, Choudhuri, Ajay, Gupta, Saurabh, Singh, S K Noushad, Ali, Gursaran Kaur, Sidhu, Parvez David, Haque, Prashant, Rahate, Aditya R, Bothra, Gyan P, Singh, Sanjiv, Maheshwari, Deepak, Jeswani, Sameer, Haveri, Apurva, Agarwal, Nilesh Radheshyam, Agrawal
Publikováno v:
Drugs
medRxiv
medRxiv
Centhaquine (LyfaquinA prospective, multicentric, randomized phase III study was conducted in patients with hypovolemic shock having systolic blood pressure (SBP) of ≤90 mm Hg and blood lactate levels of ≥2 mmol/L. Patients were randomized in a 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c81c43ba5e0546074e763e55b4b1cf49
https://pubmed.ncbi.nlm.nih.gov/34061314
https://pubmed.ncbi.nlm.nih.gov/34061314
Autor:
Gyan Singh, Prashant Rahate, Parvez David Haque, Apurva Agarwal, Anil Gulati, Rajat Choudhuri, Deepak Jeswani, Sameer Haveri, Saurabh Singh, Ajay K. Gupta, Sanjeev Maheshwari, Aditya R. Bothra, Nilesh Agrawal, S. K. Noushad Ali, Gursaran Kaur Sidhu
INTRODUCTIONCenthaquine (Lyfaquin®) showed significant safety and efficacy in preclinical and clinical phase I and II studies.METHODSA prospective, multicentric, randomized phase III study was conducted in patients with hypovolemic shock having syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edfa9743d9b1f72ab85da0984f998a4
https://doi.org/10.1101/2020.07.30.20068114
https://doi.org/10.1101/2020.07.30.20068114
